Tiotropium Inhaler Guide: Why 18 mcg and 5 mcg Are the Same Dose, and Who Actually Benefits

Tiotropium is the drug most people with COPD will be offered at some point, and one that a smaller group with severe asthma will be offered on top of their steroid inhaler. It is sold as Spiriva by Boehringer Ingelheim and as Tiova by Cipla, and its doses look wildly inconsistent: 18 mcg in a capsule, 5 mcg from a soft mist inhaler, 2.5 mcg for asthma, 9 mcg per puff from an aerosol. Those numbers describe the same treatment. Understanding why is the first step in using it properly.

This guide covers how tiotropium works, what the large trials showed in COPD and in asthma, where it sits in current treatment, the side effects alongside their placebo rates, and who should be careful with it.

What tiotropium is and how it works

Tiotropium is a long-acting muscarinic antagonist. It blocks the muscarinic receptors in the airways through which acetylcholine, released by the vagus nerve, tightens airway muscle and drives mucus secretion. In COPD that cholinergic tone is the main reversible part of the airway narrowing, which is why an anticholinergic works particularly well there.

What set tiotropium apart from the older anticholinergic ipratropium was duration. Ipratropium, the drug in Ipravent and part of Duolin, lasts a few hours and was typically given four times a day. Tiotropium is a very long-acting antimuscarinic taken once a day (PMID: 19505267). In a chronic disease where outcomes depend on taking treatment every day, once-daily dosing is a large part of why the drug succeeded.

The dose numbers that confuse everyone

Product	Device	Labeled amount	Daily regimen	Daily labeled total
Spiriva HandiHaler	Capsule powder device	18 mcg per capsule	One capsule, inhaled twice, once daily	18 mcg
Spiriva Respimat for COPD	Soft mist inhaler	2.5 mcg per puff	Two puffs once daily	5 mcg
Spiriva Respimat for asthma	Soft mist inhaler	1.25 mcg per puff	Two puffs once daily	2.5 mcg
Tiova Rotacaps	Capsule for Rotahaler or Revolizer	18 mcg per capsule	One capsule once daily	18 mcg
Tiova Inhaler	Aerosol inhaler	9 mcg per puff	Two puffs once daily	18 mcg

Three things explain the spread. A capsule dose is the amount inside the capsule, and the device releases less of it: under standardized testing the HandiHaler delivers a mean of 10.4 mcg from the 18 mcg capsule at a flow of 39 liters per minute, according to its US label. The soft mist inhaler produces a slow-moving aerosol that deposits a larger fraction in the lungs, so it needs less drug to start with. And Cipla's aerosol inhaler splits an 18 mcg daily total into two puffs of 9 mcg. The number on the label tells you what is in the device, not what reaches the airways.

TIOSPIR: evidence that different numbers are the same dose

For several years the two Spiriva formulations were not assumed to be equivalent. Pooled data had shown more deaths with the soft mist inhaler than with placebo, while the HandiHaler had been associated with lower mortality than placebo. The TIOSPIR trial was designed to settle it. It randomized 17,135 people with COPD to tiotropium soft mist 2.5 mcg or 5 mcg, or HandiHaler 18 mcg, once daily, and followed them for a mean of 2.3 years. Patients with stable heart disease, including arrhythmias, were allowed to take part (PMID: 23992515).

Arm	Patients	Deaths	Hazard ratio for death vs HandiHaler
Soft mist 2.5 mcg	5,730	440 (7.7%)	1.00 (95% CI 0.87 to 1.14)
Soft mist 5 mcg	5,711	423 (7.4%)	0.96 (95% CI 0.84 to 1.09)
HandiHaler 18 mcg	5,694	439 (7.7%)	Reference

Mortality, time to first exacerbation (hazard ratio 0.98 for the 5 mcg dose against HandiHaler) and major cardiovascular events (3.9, 3.9 and 3.6 percent) were all similar. The 5 mcg soft mist dose and the 18 mcg capsule are, for practical purposes, the same treatment delivered by different machines.

One limit is worth stating. TIOSPIR tested Boehringer's own devices. Tiova Rotacaps contain the same 18 mcg per capsule but are inhaled through a Rotahaler or Revolizer rather than a HandiHaler, and the fraction delivered depends on the device and on the patient's breath. The large outcome trials do not directly cover that combination.

What tiotropium does in COPD: the four-year evidence

UPLIFT was a four-year, placebo-controlled trial of tiotropium 18 mcg by HandiHaler in 5,993 people with moderate to very severe COPD, mean age 65, with post-bronchodilator FEV1 averaging 48 percent of predicted. Patients in both arms could keep using any other respiratory medicine except inhaled anticholinergics, so the results measure what tiotropium added on top of usual care (PMID: 18836213).

Outcome	Result
FEV1 before bronchodilator	87 to 103 mL higher with tiotropium, maintained for four years
Rate of FEV1 decline after day 30	No significant difference
Risk of an exacerbation	14% lower (hazard ratio 0.86, 95% CI 0.81 to 0.91)
Exacerbation-related hospitalization	14% lower (hazard ratio 0.86, 95% CI 0.78 to 0.95)
Median time to first exacerbation	16.7 months vs 12.5 months
All-cause mortality	No significant difference from placebo

The time to first exacerbation is the row that matters most to patients: about four extra months, on average, before the first flare. The exacerbation, hospitalization and mortality figures are as reported in the Spiriva HandiHaler prescribing information's description of the trial.

What it does not do

UPLIFT was designed to test whether tiotropium slows the long-term loss of lung function in COPD. It did not. After the first month the rate of FEV1 decline was the same in both arms (PMID: 18836213). Tiotropium improves lung function by a stable margin and reduces flares, but it does not change the trajectory of the disease. Stopping smoking is the intervention with the strongest evidence for doing that.

It is also not a reliever. The label describes tiotropium as once-daily maintenance treatment and states it is not for initial treatment of acute bronchospasm. Anyone taking it still needs a fast-acting reliever such as Asthalin or Levolin for breakthrough breathlessness.

Where tiotropium sits in COPD treatment now

For most of its history tiotropium was prescribed on its own as the first long-acting treatment in COPD. Current guidance has moved. The GOLD 2025 report recommends a long-acting muscarinic antagonist combined with a long-acting beta agonist as the preferred starting treatment for patients with significant symptoms (group B) and for those with exacerbations (group E). A single bronchodilator remains an option for patients with few symptoms and no exacerbations (group A), or when a combination is not appropriate. An inhaled steroid is added only for patients with exacerbations and a blood eosinophil count of 300 cells per microliter or more.

In practical terms, tiotropium alone is increasingly the starting point for milder COPD, and tiotropium with formoterol the starting point for most other patients. We stock that combination as Duova Inhaler (tiotropium 9 mcg with formoterol 6 mcg per puff) and Duova Rotacaps (18 mcg with 12 mcg per capsule).

COPD patients who also have features of asthma are a different group. GOLD advises treating them according to asthma guidelines, which makes an inhaled steroid mandatory.

Tiotropium in asthma: an add-on, not a starting point

In asthma the logic runs the other way. Asthma is primarily an inflammatory disease, an inhaled steroid is the foundation, and tiotropium enters only when a steroid with a long-acting beta agonist is not enough.

The key evidence is two replicate trials published together, in 912 adults whose asthma stayed uncontrolled despite an inhaled steroid and a long-acting beta agonist, all with at least one severe exacerbation in the previous year. Adding tiotropium 5 mcg by soft mist inhaler for 48 weeks produced the following against placebo (PMID: 22938706):

Outcome	Trial 1	Trial 2
Peak FEV1 improvement	86 mL	154 mL
Trough FEV1 improvement	88 mL	111 mL
Time to first severe exacerbation (pooled)	282 days vs 226 days; hazard ratio 0.79, a 21% lower risk

No deaths occurred and adverse events were similar in both groups. The benefit is modest extra bronchodilation and fewer severe attacks in a group with hard-to-control disease. That is a real option for that group, which is why asthma guidelines include add-on tiotropium for patients who remain uncontrolled on an inhaled steroid with a long-acting beta agonist, and why the soft mist inhaler has been approved in the United States as once-daily asthma maintenance for patients aged 6 and over (PMID: 29368127).

The asthma rule: never instead of the inhaled steroid

A long-acting muscarinic antagonist should not be the only controller in asthma. Every trial that showed benefit added it on top of an inhaled steroid, and treating asthma with bronchodilators while leaving the inflammation untreated is the pattern guidelines have moved away from because of the risk of severe attacks (PMID: 38237858). If tiotropium is prescribed for asthma, it sits alongside a steroid inhaler such as Foracort or Seroflo, whose differences are covered in our Advair vs Symbicort comparison. It never replaces one.

Triple therapy in one inhaler

Triohale combines tiotropium, formoterol and the inhaled steroid ciclesonide in one device, as an aerosol (9 mcg, 6 mcg and 200 mcg per puff) and as Rotacaps (18 mcg, 12 mcg and 400 mcg per capsule). Single-inhaler triple therapy has trial support in COPD patients who keep having exacerbations (PMID: 33252985) and in asthma that remains uncontrolled on a steroid with a long-acting beta agonist (PMID: 31582314).

Those trials used other molecule combinations, glycopyrronium rather than tiotropium, and budesonide or beclometasone rather than ciclesonide. The case for this specific trio is extrapolated from the class rather than tested directly. In COPD, the case for any triple therapy depends on exacerbation history and eosinophil count, as above.

Side effects, with the placebo column

The largest safety dataset comes from the four-year trial, in which 2,986 patients took tiotropium 18 mcg daily. The prescribing information lists the adverse reactions that occurred in at least 3 percent of tiotropium patients and exceeded placebo by at least 1 percentage point:

Reaction	Tiotropium	Placebo	Excess
Pharyngitis	12.5%	10.8%	1.7 points
Sinusitis	6.5%	5.3%	1.2 points
Headache	5.7%	4.5%	1.2 points
Constipation	5.1%	3.7%	1.4 points
Dry mouth	5.1%	2.7%	2.4 points
Depression	4.4%	3.3%	1.1 points
Insomnia	4.4%	3.0%	1.4 points
Arthralgia	4.2%	3.1%	1.1 points

Subtract the placebo column and the picture is quiet. Dry mouth has the largest excess at 2.4 percentage points, and it is the most commonly reported adverse reaction across the tiotropium program. It is usually mild and often resolves with continued treatment. Everything else sits at an excess of between one and two percentage points. In the one-year trials, dry mouth, constipation and urinary tract infection became more common with age.

A systematic review of serious adverse event data concluded that serious events occurred at the same rate as with placebo (PMID: 19505267), and TIOSPIR found no difference in major cardiovascular events between the formulations, in a population that included people with stable heart disease.

Who should be careful with tiotropium

• Narrow-angle glaucoma. Anticholinergics can raise pressure inside the eye. Eye pain, blurred vision, halos around lights or red eyes after starting tiotropium need urgent assessment. Keep the powder and spray away from the eyes.
• Urinary retention or an enlarged prostate. Difficulty passing urine or painful urination is a reason to stop and contact the prescriber.
• Kidney impairment. Tiotropium is cleared mainly by the kidneys. The label advises close monitoring for anticholinergic side effects when creatinine clearance is below 60 mL/min.
• Allergy to ipratropium or related drugs. Hypersensitivity to tiotropium or ipratropium is a contraindication.
• Other anticholinergic medicines. The label advises avoiding combination with other anticholinergic-containing drugs. That includes ipratropium, so regular Duolin or Ipravent alongside Tiova duplicates the same drug class. A plain short-acting beta agonist is the usual reliever partner.
• Paradoxical bronchospasm. Wheezing that gets worse immediately after a dose means stop and seek assessment.

Using each Tiova device

Tiova Rotacaps: one 18 mcg capsule once daily through a Rotahaler or Revolizer, with a fast, deep breath, checking afterwards that the capsule is empty. The instructions for the original HandiHaler tell patients to inhale twice from each capsule, and the principle behind that, that a single breath may not empty a capsule, applies to any capsule device.

Tiova Inhaler: two puffs of 9 mcg once daily with slow, deep breaths, ideally through a spacer. Tiova Synchrobreathe is the same dose in a breath-actuated device that fires as you inhale.

Which device suits whom, and the technique errors that matter most for each, are covered in our guide to Rotacaps, inhalers and respules.

Timing, missed doses and double doses

Take tiotropium once a day at about the same time. It is a maintenance treatment, and using it only on bad days does not reproduce the benefits seen in the trials. If a dose is missed, take it when remembered, but never more than once in 24 hours.

An accidental extra dose is unlikely to cause harm at these amounts. According to the US label, a single inhaled dose of up to 282 mcg in healthy volunteers produced no systemic anticholinergic effects, while repeated daily inhalation of 141 mcg produced dry mouth and conjunctivitis. That margin is not a reason to double up; an extra dose adds side effects without adding benefit.

A swallowed Rotacap delivers almost nothing, because tiotropium taken by mouth has an oral bioavailability of about 2 to 3 percent. The lungs have simply missed that dose.

What we stock

Product	Contents	Format	Price
Tiova Rotacaps	Tiotropium 18 mcg per capsule	Capsule powder	$21.00
Tiova Inhaler	Tiotropium 9 mcg per puff	Aerosol inhaler	$24.00
Tiova Synchrobreathe	Tiotropium 9 mcg per puff	Breath-actuated inhaler	$24.00
Duova Inhaler	Tiotropium 9 mcg, formoterol 6 mcg per puff	Aerosol inhaler	$32.00
Duova Rotacaps	Tiotropium 18 mcg, formoterol 12 mcg per capsule	Capsule powder	$26.00
Triohale Inhaler	Tiotropium 9 mcg, formoterol 6 mcg, ciclesonide 200 mcg per puff	Aerosol inhaler	$33.00
Triohale Rotacaps	Tiotropium 18 mcg, formoterol 12 mcg, ciclesonide 400 mcg per capsule	Capsule powder	$18.00

The short version

• In COPD, tiotropium reduces exacerbations by about 14 percent and improves breathing, but it does not slow the long-term decline in lung function.
• For most symptomatic COPD patients, GOLD now starts with tiotropium or another muscarinic antagonist combined with a long-acting beta agonist, rather than tiotropium alone.
• The 18 mcg capsule and the 5 mcg soft mist inhaler performed the same in a 17,135 patient trial.
• In asthma, tiotropium is an add-on for uncontrolled disease and never a substitute for an inhaled steroid.
• It is not a reliever. Watch for eye pain, difficulty passing urine, and duplication with ipratropium.

Medical disclaimer

This article is educational and does not replace advice from a qualified healthcare professional. Tiotropium is a prescription medicine in the United States, United Kingdom, Canada and Australia. Trial results describe specific populations and cannot be applied directly to any individual. The regimens described are those in product labeling and are not personal dosing instructions. Sudden eye pain or blurred vision, inability to pass urine, or breathing that worsens after a dose needs urgent medical assessment.

References

• Tashkin DP et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT). N Engl J Med 2008. PubMed PMID: 18836213.
• Wise RA et al. Tiotropium Respimat inhaler and the risk of death in COPD (TIOSPIR). N Engl J Med 2013. PubMed PMID: 23992515.
• Kerstjens HA et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012. PubMed PMID: 22938706.
• Efficacy and safety of tiotropium in children and adolescents. PubMed PMID: 29368127.
• Safety and pharmacological profile of tiotropium bromide. PubMed PMID: 19505267.
• Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for COPD. PubMed PMID: 33252985.
• Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER). PubMed PMID: 31582314.
• The role of ICS-containing rescue therapy versus SABA alone in asthma management today. PubMed PMID: 38237858.
• FDA prescribing information, Spiriva HandiHaler: dosage, warnings and precautions, adverse reactions, drug interactions, renal impairment, overdosage, pharmacokinetics and clinical studies sections.
• Global Initiative for Chronic Obstructive Lung Disease, 2025 report, initial pharmacological treatment.

Related reading on asthma and COPD treatment

For the two main steroid combination inhalers, see Advair vs Symbicort and our budesonide with formoterol guide. Device choice is covered in Rotacaps vs inhaler vs respules, and relievers in salbutamol vs levosalbutamol. The full range is on our asthma and respiratory medicines page.